Apellis Pharmaceuticals (APLS) VP share sale tied to RSU tax withholding

Rhea-AI Filing Summary

Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported a sale of 873 shares of Apellis common stock on January 13, 2026 at a price of $22.1872 per share. According to the filing, this sale was made to cover tax withholding on restricted stock units that were released on January 12, 2026, meaning it was tied to an equity compensation event rather than an open-market discretionary sale. Following this transaction, Chopas beneficially owned 52,595 shares of Apellis common stock in direct ownership.

Insider Trade Summary

Net Seller: 873 shares ($19,369)

Net Sell 1 txn

Insider Chopas James George

Role VP/Chief Accounting Officer

Sold 873 shs ($19K)

Type	Security	Shares	Price	Value
Sale	Common Stock	873	$22.1872	$19K

Holdings After Transaction: Common Stock — 52,595 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chopas James George

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP/Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		S(1)		873	D	$22.1872	52,595	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 12, 2026.

	/s/ David Watson, attorney-in-fact for James Chopas	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Apellis Pharmaceuticals (APLS) report for James George Chopas?

The report shows that VP and Chief Accounting Officer James George Chopas sold 873 shares of Apellis common stock on January 13, 2026 at $22.1872 per share.

Why did James George Chopas sell Apellis (APLS) shares in this Form 4 filing?

The filing explains that the 873 shares were sold to cover tax withholding on restricted stock units that were released on January 12, 2026.

How many Apellis (APLS) shares does James George Chopas own after the reported sale?

After the January 13, 2026 transaction, James George Chopas beneficially owned 52,595 shares of Apellis common stock in direct ownership.

What is the role of James George Chopas at Apellis Pharmaceuticals (APLS)?

James George Chopas is an officer of Apellis Pharmaceuticals, serving as VP/Chief Accounting Officer according to the filing.

Is the Apellis (APLS) insider transaction related to equity compensation?

Yes. The filing states that the shares sold were to cover tax withholding arising from the release of restricted stock units on January 12, 2026.